IceCure Reports Strong 5-Year Results in Kidney Cancer
CAESAREA, Israel, March 25, 2026 IceCure Medical has reported positive five-year top-line results from its ICESECRET clinical trial, demonstrating...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
CAESAREA, Israel, March 25, 2026 IceCure Medical has reported positive five-year top-line results from its ICESECRET clinical trial, demonstrating...
LAGUNA HILLS, Calif., March 19, 2026 Adagio Medical Holdings, Inc. announced successful outcomes from Expanded Access Program (EAP) cases...
CAESAREA, Israel, Sept. 15, 2025 – IceCure Medical Ltd. (NASDAQ: ICCM), a pioneer in minimally invasive cryoablation therapies, today...
